Cardiovascular Medication Use and Risk of Acute Exacerbation in Patients With Asthma-COPD Overlap (CVACO Study)

다국어 초록 (Multilingual Abstract)

Purpose: Current clinical guidelines are unclear regarding the association of cardiovascular medication with the risk of acute exacerbation (AE) in patients with asthma-chronic obstructive pulmonary disease (COPD) overlap (ACO).
Methods: We conducted a retrospective cohort study by interrogating the claims database of Taipei Veterans General Hospital. Patients with coexistent fixed airflow limitation and asthma were enrolled as an ACO cohort between 2009 and 2017. Exposure to cardiovascular medications, including angiotensin converting enzyme inhibitors (ACEIs), angiotensin II receptor blockers (ARBs), non-selective beta-blockers, cardioselective beta-blockers, dihydropyridine (DHP) calcium channel blockers (CCBs), and non-DHP CCBs, in 3-month period each served as time-dependent covariates. Patients receiving a cardiovascular medication ≥ 28 cumulative daily doses were defined as respective cardiovascular medication users. Patients were followed up until December 31, 2018. The primary endpoint was severe AE, defined as hospitalization or emergency department visit for either asthma, COPD, or respiratory failure. The secondary outcome was moderate AE.
Results: The final study cohort consisted of 582 ACO subjects, with a mean follow-up period of 2.98 years. After adjustment, ARB (hazard ratio [HR], 0.64, 95% confidence interval [CI], 0.44–0.93, P = 0.019), cardioselective beta-blocker (HR, 0.29, 95% CI, 0.11–0.72, P = 0.008) and DHP CCB (HR, 0.66, 95% CI, 0.45–0.97, P = 0.035) therapies were associated with lower risks of severe AE. ARB (HR, 0.42, 95% CI, 0.30–0.62, P < 0.001) and DHP CCB (HR, 0.55, 95% CI, 0.38–0.80, P = 0.002) therapies were associated with lower risks of moderate AE. Cardioselective beta-blockers, ARBs, and DHP CCBs were associated with lower risks of severe AE in frequent exacerbators. ACEI, non-selective beta-blocker, or non-DHP CCB use did not change the risk of severe AE.
Conclusions: ARB, cardioselective beta-blocker, and DHP CCB therapies may lower the risk of AE in patients with ACO.

참고문헌 (Reference)

1 Sin DD, "What is asthma-COPD overlap syndrome? Towards a consensus definition from a round table discussion" 48 : 664-673, 2016

2 Ni Y, "Use of cardioselective β-blockers in patients with chronic obstructive pulmonary disease : a meta-analysis of randomized, placebo-controlled, blinded trials" 40 : 2051-2065, 2012

3 Su VY, "Use of ICS/LABA combinations or LAMA is associated with a lower risk of acute exacerbation in patients with coexistent COPD and asthma" 6 : 1927-1935, 2018

4 Lipworth B, "Underuse of β-blockers in heart failure and chronic obstructive pulmonary disease" 102 : 1909-1914, 2016

5 Leong P, "The untreated treatable trait : cardiovascular disease in COPD exacerbations" 26 : 413-415, 2021

6 Su VY, "Statin use is associated with a lower risk of TB" 152 : 598-606, 2017

7 Su VY, "Sleep apnea and risk of pneumonia : a nationwide population-based study" 186 : 415-421, 2014

8 Su VY, "Real-world effectiveness of medications on survival in patients with COPD-heart failure overlap" 11 : 3650-3667, 2019

9 Grootendorst DC, "Mechanisms of bronchial hyperreactivity in asthma and chronic obstructive pulmonary disease" 1 : 77-87, 2004

10 Su VY, "Latent tuberculosis infection and the risk of subsequent cancer" 95 : e2352-, 2016

11 Valverde MA, "Ion channels in asthma" 286 : 32877-32882, 2011

12 Woo KS, "High prevalence of persistent cough with angiotensin converting enzyme inhibitors in Chinese" 40 : 141-144, 1995

13 Global Initiative for Chronic Obstructive Lung Disease, "Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease (2021 report)" Global Initiative for Chronic Obstructive Lung Disease

14 Global Initiative for Asthma, "Global strategy for asthma management and prevention" Global Initiative for Asthma 2021

15 Hosseini M, "Global prevalence of asthma-COPD overlap(ACO)in the general population : a systematic review and meta-analysis" 20 : 229-, 2019

16 Tan LD, "Further insight into the intimate relationship between asthma and cardiovascular disease" 159 : 1311-1312, 2021

17 Hirota K, "Effects of three different L-type Ca2+ entry blockers on airway constriction induced by muscarinic receptor stimulation" 90 : 671-675, 2003

18 Chapman RW, "Effect of extra-and intracellular calcium blockers on histamine and antigen-induced bronchospasms in guinea pigs and rats" 29 : 282-291, 1984

19 Yamakage M, "Different inhibitory effects of volatile anesthetics on T-and L-type voltage-dependent Ca2+ channels in porcine tracheal and bronchial smooth muscles" 94 : 683-693, 2001

20 Ingebrigtsen TS, "Coronary heart disease and heart failure in asthma, COPD and asthma-COPD overlap" 7 : e000470-, 2020

21 Rabe KF, "Cardiovascular disease and COPD : dangerous liaisons?" 27 : 180057-, 2018

22 Salpeter SR, "Cardioselective beta-blockers in patients with reactive airway disease : a meta-analysis" 137 : 715-725, 2002

23 Salpeter S, "Cardioselective beta-blockers for chronic obstructive pulmonary disease" 2005 : CD003566-, 2005

24 Wood R, "Bronchospasm and cough as adverse reactions to the ACE inhibitors captopril, enalapril and lisinopril. A controlled retrospective cohort study" 39 : 265-270, 1995

25 Kaufman J, "Bronchial hyperreactivity and cough due to angiotensin-converting enzyme inhibitors" 95 : 544-548, 1989

26 Yang YL, "Association of β-blocker use with survival and pulmonary function in patients with chronic obstructive pulmonary and cardiovascular disease : a systematic review and meta-analysis" 41 : 4415-4422, 2020

27 Miravitlles M, "Algorithm for identification of asthma-COPD overlap : consensus between the Spanish COPD and asthma guidelines" 49 : 1700068-, 2017

28 Deyo RA, "Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases" 45 : 613-619, 1992